Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5137-5142

  Specenier, Pol M ^a   Van Den Brande, Jan ^a   Schrijvers, Dirk ^a,b   Huizing, Manon T ^a   Altintas, Sevilay ^a   Dyck, Joke ^a   Van Den Weyngaert, Danielle ^a   Van Laer, Carl ^a   Vermorken, Jan B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b ZNA Middelheim ^*  (Belgium)

Author keywords

Cisplatin; Docetaxel; Head and neck cancer; Ifosfamide

Indexed keywords

CIPROFLOXACIN; CISPLATIN; DOCETAXEL; ERYTHROPOIETIN; GEMCITABINE; IFOSFAMIDE; MESNA; METHYLENE BLUE; METHYLPREDNISOLONE; ONDANSETRON;

ACUTE DISEASE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HEART INFARCTION; HUMAN; LEUKOPENIA; LYMPH NODE METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SEPSIS; SQUAMOUS CELL CARCINOMA; STANDARD; THROMBOCYTOPENIA; TOXICOLOGY; TREATMENT RESPONSE; TUMOR VOLUME; VASCULAR DISEASE; VOMITING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CISPLATIN; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IFOSFAMIDE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TAXOIDS;

EID: 75149160942     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Specenier PM and Vermorken JB: Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol 45: 409-415, 2009.
2. Specenier PM and Vermorken JB: Recurrent head and neck cancer: current treatment and future prospects. Expert Rev Anticancer Ther 8: 375-391, 2008.
3. Verweij J, Alexieva-Figusch J, de Boer MF, Reichgelt B and Stoter G: Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group. Eur J Cancer Clin Oncol 24: 795-796, 1988.
4. Cervellino JC, Araujo CE, Pirisi C, Francia A and Cerruti R: Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study. Oncology 48: 89-92, 1991.
5. Buesa JM, Fernandez R, Esteban E, Estrada E, Baron FJ, Palacio I et al: Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. Ann Oncol 2: 151-152, 1991.
6. Martin M, Diaz-Rubio E, Gonzalez Larriba JL, Casado A, Sastre J, Lopez-Vega et al: Ifosfamide in advanced epidermoid head and neck cancer. Cancer Chemother Pharmacol 31: 340-342, 1993.
7. Huber MH, Lippman SM, Benner SE, Shirinian M, Dimery IW, Dunnington JS and Hong WK: A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. Am J Clin Oncol 19: 379-382, 1996.
8. Sandler A, Saxman S, Bandealy M, Heilman D, Monaco F, McClean J and Arquette M: Ifosfamide in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck: a phase II Hoosier Oncology Group trial. Am J Clin Oncol 21: 195-197, 1998.
9. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM et al: Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14: 1672-1678, 1996.
10. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J et al: Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5: 533-553, 1994.
11. Inuyama Y, Kataura A, Togawa K, Saijo S, Satake B, Takeoda S et al: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer. Gan To Kagaku Ryoho 26: 107-116, 1999.
12. Couteau C, Chouaki N, Leyvraz S, Oulid-Aissa D, Lebecq A, Domenge C et al: A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 81: 457-462, 1999.
13. Hitt R, Amador ML, Quintela-Fandino M, Jimeno A, del Val O, Hernando S and Cortes-Funes H: Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. 106: 106-111, 2006.
14. O'Dwyer PJ, Johnson SW and Hamilton TC: Cisplatin and its analogues. In: Cancer Principles and Practice of Oncology, 5th Edition. DeVita VT, Hellman S and Rosenberg SA (eds.). Philadelphia, Lippincott-Raven Publishers, pp. 418-432, 1997.
15. Teicher BA: Antitumor alkylating agents. Cisplatin and its analogues. In: Cancer Principles and Practice of Oncology, 5th Edition. DeVita VT, Hellman S and Rosenberg SA (eds.). Philadelphia, Lippincott-Raven Publishers, pp. 405-418, 1997.
16. Rowinski EK and Donehouwer RC: Antimicrotubule agents. In: Cancer Principles and Practice of Oncology, 5th Edition. DeVita VT, Hellman S and Rosenberg SA (eds). Philadelphia, Lippincott-Raven Publishers, pp. 418-432, 1997.
17. Specenier P, Rasschaert M, Van den Brande J, Dyck J, Schrijvers D, Huizing MT and Vermorken JB: Docetaxel, ifosfamide and cisplatin (DIP) in solid tumor treatment: A phase I study. Submitted.
18. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
19. Arbuck SG, Ivy SP, Setser A et al: The Revised Common Toxicity Criteria: Version 2.0. CTEP Website, http://ctep.info.nih.gov, 1999.
20. Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prové A and Vermorken JB: Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 82: 291-294, 2000.
21. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al: 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24: 3187-3205, 2006.
22. Greil R, Psenak O and Roila F; ESMO Guidelines Working Group: Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol 19(Suppl 2): ii116-118, 2008.
23. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M et al: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42: 2433-2453, 2006.
24. Mantovani G, Ghiani M, Lai P, Maccio A, Dessi D, Succu G et al: Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neoadjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study. Oncol Rep 5: 1499-1505, 1998.
25. Pai VR, Mazumdar AT, Deshmukh CD, Bakshi AV, Parikh DM, Parikh PM et al: Neoadjuvant chemotherapy with ifosfamide and cisplatin combination in advanced head and neck cancer: a retrospective analysis of 519 patients: a single institution experience. Med Oncol 20: 1-5, 2003.
26. Sanchez Parra M, Churruca C, Paredes A, Lacasta A, Lopez de Argumedo G, Alvarez I et al: Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma. Am J Clin Oncol 22: 6-7, 1999.
27. Recchia F, Saggio G, Cesta A, Amiconi G, di Blasio A, Candeloro G et al: Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. Anticancer Res 26: 2317-2324, 2006.
28. Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E Jr et al: Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 95: 322-330, 2002.
29. Hancock SB, Krempl GA, Canfield V, Bogardus C, Kojouri K, Kaneaster SK and Medina JE: Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy. Laryngoscope 118: 1357-1361, 2008.
30. Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A et al: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23: 8636-8645, 2005.
31. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357: 1705-1715, 2007.
32. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357: 1695-1704, 2007.
33. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J et al: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101: 498-506, 2009.
34. Bernier J, Coens C, Remenar E, Van Herpen C, Germa Lluch J, Stewart S et al: Impact on quality of life (QoL) of the addition of docetaxel (T) to neoadjuvant cisplatin plus 5-fluorouracil treatment in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN): EORTC study 24971. J Clin Oncol 24(18S): 5522 (Abstract), 2006.
35. Hitt R, Grau J, Lopez-Pousa JA, Berrocal A, Garcia Giron C, Irigoyen A et al: Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 27(15s): 6009 (Abstract), 2009.
36. Paccagnella A, Buffoli A, Koussis H, Gava A, Franceschi T, Gardani G et al: Concomitant chemoradiotherapy (CT/RT) vs. neoadjuvant chemotherapy with docetaxel/cispaItin/5-fluorouracil (TPF) followed by CT/RT in locally advanced head and neck cancer. Final results of a phase II randomized study. J Clin Oncol 26(20S): 6000 (Abstract), 2008.